Why the study?
Is diabetic proteinuria a modifiable determinant of renal progression and a valid surrogate endpoint for clinical trials?
Is diabetic proteinuria a modifiable determinant of renal progression and a valid surrogate endpoint for clinical trials?
This review highlights the potential of proteinuria as a surrogate endpoint for renal progression in diabetic nephropathy, emphasizing the need for further validation with non-RAAS blocking agents.
Proteinuria may support surrogate use in diabetic nephropathy trials; leaves open validation beyond RAAS blockade.
BACKGROUND/AIMS: Proteinuria, nearly a universal finding in progressive kidney disease, has been the subject of frequent recent analyses in the renal literature. Proteinuria is a hallmark of diabetic nephropathy: microalbuminuria is the principal early predictor for progression of diabetic glomerulopathy, and proteinuria may be viewed as a measure of the severity and promoter of progression of nephropathy. METHODS: This article critically reviews for the first time the full scope of diabetic proteinuria--complex molecular mechanisms, natural history, and analysis of treatment trials--in order to address the validity of 'the proteinuria hypothesis', i.e., that diabetic proteinuria is a modifiable determinant of renal progression. This hypothesis is analyzed in detail, including recent studies on the primary therapy of diabetic nephropathy, renin-angiotensin blockade. RESULTS: As fully developed, this hypothesis consists of three postulates: that higher amounts of proteinuria predict progressive loss of function, that proteinuria reduction correlates with slowing progression, and that proteinuria is a surrogate endpoint for clinical trials. The latter postulate has not before been adequately linked to growing information about the first two postulates as they apply to diabetic kidney disease. CONCLUSION: While diabetic nephropathy is a disease model for the potential use of proteinuria as a surrogate marker for renal progression, this shift in perspective will require prospective data from additional clinical trials, particularly of non-renin-angiotensin blocking drugs, to be complete.
No takes yet. Share an insight, caveat, or question.
Mark E. Williams (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: